At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Blood & Urine Samples (other), Imaging (other)
- How long the study runs
- Study runs about 157 months (dates as stated)
- About the drug or intervention
- Blood & Urine Samples — other: Blood and urine samples will be collected to help identify biomarkers that can be used to detect liver cancer at the earliest possible time · Imaging — other: MRI \& MRE Scans
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years to 100 Years
- Who
- All
- Number of participants
- 250
- Started
- 2022-05-23
- Last checked
- 2022-09
Plain English Summary
What is this study?
- • Testing a new treatment for hepatocellular carcinoma
- • Clinical study - 250 participants
- • The SELINA study will recruit 200 patients with cirrhosis and small HCC and 50 patients with HCC but without cirrhosis (most of whom are expected to have FLD)
Who can take part?
- • Ages 18 Years to 100 Years
- • Diagnosed with hepatocellular carcinoma
Where?
- • Oxford - Hepatology Clinical Trial Unit, John Radcliffe Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The SELINA study will recruit 200 patients with cirrhosis and small HCC and 50 patients with HCC but without cirrhosis (most of whom are expected to have FLD). Blood, urine and liver tissue samples (where available) will be collected for laboratory analysis. In a subgroup of patients (N=80, around 64 patients with HCC with liver cirrhosis and around 16 patients with HCC without liver cirrhosis), additional magnetic resonance liver imaging will be performed. The findings of the SELINA study aim to identify biomarkers that can be used to detect liver cancer at the earliest possible time, something we expect will increase the survival rate of HCC.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 100 Years
- Who can join: All genders
What the study is looking for
- ✓Participant is willing and able to give agreement to take part for participation in the study.
- ✓Male or Female aged 18 years or above.
- ✓Diagnosed with small HCC (Barcelona Clinic Liver Cancer Staging Criteria (BCLC) stage 0/A; 1-3 nodules \<3cm,...
- ✓Diagnosed with small HCC (as above) and without cirrhosis
- ✓Diagnosis of small HCC shown or confirmed within 3 months of study Visit 1
Who cannot take part
- ✗Patients judged by the investigator to be unsuitable for inclusion in the study (e.g. where the investigator feels...
- ✗HCC with liver cirrhosis at BCLC stage B/C
- ✗Patients who have had a previous liver transplant (note, it is permitted to enrol patients on the liver transplant...
- ✗Participants of the Pearl study
- ✗Patients who have had a previous diagnosis of HCC followed by therapy, and now have a recurrence at the same site in...
See the full criteria
Where Is This Study? (1 UK site)
Hepatology Clinical Trial Unit, John Radcliffe Hospital
Oxford OX3 9DU, United Kingdom
How to Get in Touch
Clinical Study Coordinator
Sponsor contactCONTACT
